Methylprednisolone and 60-Day in Hospital Survival in COVID-19 Pneumonia: Erratum

In the following article in the July 2021 issue of the Journal, there were multiple errors.

• 1. On page 6 of the article, in the second and third sentences of the second paragraph should have been:

HD MP 7–14 days was associated with higher mortality compared with LD MP greater than or equal to 14 days (HR, 2.42; 95% CI, 1.17–5.03; p = 0.0174). HD MP greater than or equal to 14 days was associated with prolonged survival compared with HD MP less than or equal to 7 days (HR, 0.28; 95% CI, 0.12–0.66; p = 0.0035).

• 2. In the RESULTS section, Primary Analysis subsection, the following should have been:

In the PS matched sample, 99 out of 380 NMP and 143 out of 379 MP patients expired, although the difference in hospital overall survival between the MP (median, 25.0 d; 95% CI, 22.0–32.0 d) and NMP (median, 19.0 d; 95% CI, 14.0–25 d) was statistically significant (stratified log-rank p < 0.0001) (Tables 1 and 2).

The analysis of the propensity matched scored sample showed that MP was associated with statistically and significantly longer in hospital survival (HR, 0.44; 95% CI, 0.33–0.60; p < 0.0001), adjusted by Fio₂ survival time interaction.

The difference in hospital survival between NMP (median, 25.0 d; 95% CI, 22.0–32.0 d) and LD MP (median, 39.0 d; 95% CI, 27.0–not available [NA] d) and HD MP (median, 20.0 d; 95% CI, 17.0–24 d) was statistically significant (stratified log-rank p < 0.0001).

The difference in hospital survival between the MP dose less than or equal to 7 days (median, 19.0 d; 95% CI, 17.0–23.0 d), MP dose 7–14 d (median, 30.0 d; 95% CI, 19.0–NA d), and MP dose greater than 14 days (median, 44.0 d; 95% CI, 32.0–60 d) was statistically significant (log-rank p = 0.0011)